Omnicell (NASDAQ:OMCL) Price Target Cut to $36.00 by Analysts at JPMorgan Chase & Co.

Omnicell (NASDAQ:OMCL) had its price objective cut by stock analysts at JPMorgan Chase & Co. from $44.00 to $36.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 6.07% from the stock’s previous close.

Other research analysts also recently issued reports about the company. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, March 6th. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Benchmark restated a “buy” rating and issued a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Finally, Bank of America reduced their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Down 2.7 %

NASDAQ:OMCL opened at $33.94 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The firm has a market cap of $1.59 billion, a PE ratio of 125.71, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a 50-day moving average of $39.77 and a 200 day moving average of $42.91. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.75.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, research analysts anticipate that Omnicell will post 1.09 EPS for the current fiscal year.

Institutional Trading of Omnicell

Several large investors have recently bought and sold shares of OMCL. Pier Capital LLC acquired a new stake in shares of Omnicell during the third quarter worth $5,859,000. Royce & Associates LP acquired a new stake in Omnicell during the 3rd quarter worth about $811,000. Geode Capital Management LLC lifted its position in Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock worth $48,176,000 after acquiring an additional 2,877 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after purchasing an additional 259,463 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Omnicell in the third quarter valued at about $753,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.